Evidence map›Paper›PMID 42429096›Full record

ArticleOtolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery2026

Development of Novel mRNA Classifiers to Stratify Preoperative Thyroid Tumor Risk.

Thomas F Barrett, Mohamed Jama, Mohammed Alshalalfa, Theresa Tharakan, Yangyang Hao, Joshua P Klopper, Taylor B Cavazos, Ryan S Jackson, Patrik Pipkorn, Jason T Rich and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Thomas F BarrettDepartment of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID https://orcid.org/0000-0002-6058-1404
Mohamed JamaDepartment of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.
Mohammed AlshalalfaVeracyte Inc., South San Francisco, California, USA.
Theresa TharakanDepartment of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.
Yangyang HaoVeracyte Inc., South San Francisco, California, USA.
Joshua P KlopperVeracyte Inc., South San Francisco, California, USA.
Taylor B CavazosVeracyte Inc., South San Francisco, California, USA.
Ryan S JacksonDepartment of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.
Patrik PipkornDepartment of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.
Jason T RichDepartment of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.
Paul A ZolkindDepartment of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.
Douglas R AdkinsRobert Ebert and Greg Stubblefield Head and Neck Tumor Center at the Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA.
Peter OppeltRobert Ebert and Greg Stubblefield Head and Neck Tumor Center at the Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA.
Anthony J ApicelliRobert Ebert and Greg Stubblefield Head and Neck Tumor Center at the Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA.
Nikhil RammohanRobert Ebert and Greg Stubblefield Head and Neck Tumor Center at the Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA.
Taylor C BrownDepartment of Surgery, Section of Surgical Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
Sidharth V PuramDepartment of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.
Sina JasimDepartment of Medicine, Division of Endocrinology, Washington University School of Medicine, St. Louis, Missouri, USA.
R Alex HarbisonDepartment of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID https://orcid.org/0000-0002-4695-6142

Funding

Polyamine blockade and anti-tumor immunity in head and neck squamous cell carcinomaK08DE034837 · NIDCR · WASHINGTON UNIVERSITY · PI Richard Alexander Harbison · 2025 to 2026
$340k
American Head and Neck Society : Young Investigator AwardBurroughs Wellcome Fund Dean's Scholars Award from the Washington University Division of Physician-ScientistsNIDCR NIH HHS K08 DE034837NIDCR NIH HHS K08DE034837
6 · The paper itself

Abstract

objectiveDevelop a preoperative risk classifier for guiding the extent of surgery in differentiated thyroid carcinomas (DTCs) under 4 cm. STUDY

designIn silico study, validation with retrospective cohort.

settingGenomic data repositories, academic tertiary medical center.

methodsPrognostic transcriptional groups and American Thyroid Association (ATA) risk groups in The Cancer Genome Atlas (TCGA) were used to create novel Clinico-TRanscriptomic (CTR) groups. Differential gene expression (DGE) was performed. Consensus clustering was used to assess the reproducibility of genomic and histologic features in: (1) Bethesda V/VI fine-needle aspirates (FNA) from the Afirma Genomic Sequencing Classifier (GSC) database (GC cohort); (2) thyroid carcinomas annotated by ATA histopathologic risk group (surgical cohort); (3) independent surgical cohort.

resultsWithin TCGA (n = 451), CTR-Low was enriched with BRAF

conclusionThe POINT classifier is predictive of genomic alterations and ATA risk in independent data sets. This study advances precision oncology, shifting the paradigm from size-based toward individualized, biology-driven care.

Indexed as

RNA, MessengerThyroid NeoplasmsBiopsy, Fine-NeedleFemaleGene Expression ProfilingHumansMutationRetrospective StudiesRisk AssessmentThyroidectomyRNA, MessengerAfirmaclusteringprognostic gene signaturethyroid cancerthyroid nodule

Identifiers

PMID42429096
PMCPMC13525898

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.